-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Atrial fibrillation (AF) and valvular heart disease (VHD) often coexist.
Aortic valve stenosis is one of the most common subtypes of VHD in developed countries, affecting a large proportion of the elderly
.
Stenosis and AF increase with age and rapidly increase with the aging of the population.
Diagnosis and prevention of blood clots
Guidelines for the use of non-vitamin K antagonist oral anticoagulants (NOAC) in AF patients with aortic valve stenosis are based on studies that included a small number of patients with aortic valve stenosis
.
Recently, the heart blood vessels published a research article on the disease areas authoritative magazine JAHA, the purpose of the study was to assess the effects of warfarin and NOAC with aortic stenosis in patients with AF thromboembolism and major bleeding
Guide blood vessels
The researchers simulated a targeted experiment using observational data from the Danish National Registry from 2013 to 2018
.
Thromboembolism is defined as a hospital diagnosis of ischemic stroke and/or systemic embolism, while massive hemorrhage is defined as intracranial hemorrhage, gastrointestinal hemorrhage, or severe or clinically relevant hemorrhage at other anatomical sites
Stroke
A total of 3726 AF and aortic stenosis patients in the study received NOAC (2357 patients) or warfarin (1369 patients) treatment prescriptions, and met the criteria of the trial
.
During the 3-year follow-up period, in the intention-to-treat analysis, compared with warfarin, the adjusted risk ratios for thromboembolism and major bleeding in NOAC-treated patients were 1.
In this observational study, the researchers observed that compared with warfarin, patients with AF and aortic stenosis treated with NOAC had a higher risk of thromboembolism, but a lower risk of major bleeding
.
This observation needs to be further validated in large randomized trials of these common patients
The researchers observed that compared with warfarin, patients with AF and aortic stenosis treated with NOAC had a higher risk of thromboembolism, but a lower risk of major bleeding
Original source:
Line Melgaard,et al.
